---
title: "QuidelOrtho 2025 EPS, revenue guidance ranges include consensus"
date: "2025-02-13 01:24:50"
summary: "QuidelOrtho (NASDAQ:QDEL) has set 2025 guidance ranges for EPS and revenue that both include the consensus figure. Adjusted diluted EPS is projected at $2.07-$2.57. Consensus is $2.45. Revenue is estimated at $2.6B-$2.81B. Consensus is $2.77B. In Q4 2025, the diagnostics testing company beat on both lines. In the quarter, on..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499205246/image_499205246.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* QuidelOrtho (NASDAQ:[QDEL](https://seekingalpha.com/symbol/QDEL "QuidelOrtho Corporation")) has set 2025 guidance ranges for EPS and revenue that both include the consensus figure.
* Adjusted diluted EPS is projected at $2.07-$2.57. Consensus is $2.45. Revenue is estimated at $2.6B-$2.81B. Consensus is $2.77B.
* In Q4 2025, the diagnostics testing company [beat on both lines](https://seekingalpha.com/news/4407233-quidel-non-gaap-eps-of-0_63-beats-by-0_05-revenue-of-707_8m-beats-by-10_78m "beat on both lines").
* In the quarter, on a non-GAAP basis, QuideOrtho swung to a loss of $153.4M (-$2.28 diluted EPS) compared to a gain of $7M ($0.10 diluted EPS) in the year-ago period.
* The company was hurt in the quarter by a year-over-year revenue decline, as well as an increase in cost of sales and a $78.7M goodwill impairment charge.
* QuidelOrtho ended 2024 with $98.3M in cash and cash equivalents compared to $118.9M at the end of 2023.

[seekalpha](https://seekingalpha.com/news/4407311-quidelortho-2025-eps-revenue-guidance-ranges-include-consensus)
